Capricor Therapeutics Overview
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is at the center of a securities class action lawsuit that may concern many of its investors. This situation stems from misrepresentations by the company regarding crucial data from their Phase 2 HOPE-2 trial of deramiocel, a promising treatment aimed at cardiomyopathy related to Duchenne muscular dystrophy. Such occurrences emphasize the importance of transparency in clinical trial results and their subsequent implications on investor confidence.
The Lawsuit Details
The lawsuit claims that between October 9, 2024, and July 10, 2025, investors were misled about the efficacy and safety data of Capricor’s leading cell therapy candidate. The allegations suggest that these misrepresentations significantly impacted the stock’s performance during this time frame. Affected shareholders are encouraged to consider stepping forward to explore their legal rights regarding this situation.
Who Can Take Action?
If you are a shareholder of Capricor and suffered substantial losses, you may want to consider serving as a lead plaintiff. This role would allow you to advocate on behalf of other investors in the class-action process. However, being a lead plaintiff is not a requirement to receive any potential recovery; you could remain an absent class member if you choose not to act.
Understanding Your Rights
As per the law firm Bernstein Liebhard LLP, which is handling the case, their representation operates on a contingency fee basis. This means that stakeholders do not incur any upfront legal fees and only pay if the firm successfully recovers funds on their behalf. This offers a risk-free opportunity for investors to explore their legal rights without immediate financial burden.
Company’s Background and Legal Precedents
Established in 1993, Bernstein Liebhard LLP has successfully recovered significant sums for its clients, reportedly over $3.5 billion. This firm has built a strong reputation in the field of securities law, representing both institutional and individual investors. The experience and historical success of the firm reflect their capability in navigating complex securities litigation, which could potentially benefit Capricor investors facing losses.
Next Steps for Investors
For those interested in pursuing legal action, it’s advised to act quickly. Documents must be filed by September 15, 2025, to be eligible for participation as lead plaintiff. Potential plaintiffs should compile relevant purchase documents and be prepared to share the details of their investments in Capricor. Engaging with experienced legal counsel can further enhance your understanding of the process and your rights.
Contact Information for Legal Assistance
Investors looking for more information on how to proceed with their claims can reach out to Bernstein Liebhard LLP. Peter Allocco, Investor Relations Manager for the firm, is available via phone at (212) 951-2030 or through email for any inquiries related to this class action lawsuit.
Frequently Asked Questions
What does the lawsuit against Capricor entail?
The lawsuit alleges that Capricor made misleading statements regarding the safety and efficacy of its lead therapy candidate, potentially impacting stock value.
How can investors participate in the class action?
Shareholders may opt to serve as lead plaintiffs and must submit required paperwork by certain deadlines to take part in the litigation process.
What are the costs associated with legal representation?
Bernstein Liebhard LLP operates on a contingency fee model, meaning investors pay no upfront costs and the firm is only compensated upon successful recovery.
Is there a time limit to file for this lawsuit?
Yes, interested parties must file their claims by September 15, 2025, to potentially serve as lead plaintiffs in the case.
Who should I contact for more information?
Investors can contact Bernstein Liebhard LLP directly via phone or email for guidance regarding their participation in the class action lawsuit.
